SALL4 and acute myeloid leukemia: And a study that was carried out by Wang et al., (2013) at Harvard Medical School, Boston, USA on 55 denovoux MDS, 20 AML on top of MDS, 16 post-treatment MDS patients and 10 healthy donors and evaluated their SALL4 expression in different WHO subtypes and international prognostic scoring system (IPSS) risk groups.